These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23441215)

  • 21. Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer.
    Labovsky V; Martinez LM; Calcagno ML; Davies KM; García-Rivello H; Wernicke A; Feldman L; Giorello MB; Matas A; Borzone FR; Howard SC; Chasseing NA
    Tumour Biol; 2016 Oct; 37(10):13377-13384. PubMed ID: 27460086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer.
    Guo X; Zhu SX; Brunner AL; van de Rijn M; West RB
    Breast Cancer Res; 2013 Dec; 15(6):R117. PubMed ID: 24342436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression.
    Chen JY; Li CF; Kuo CC; Tsai KK; Hou MF; Hung WC
    Breast Cancer Res; 2014 Jul; 16(4):410. PubMed ID: 25060643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    Muranen TA; Blomqvist C; Dörk T; Jakubowska A; Heikkilä P; Fagerholm R; Greco D; Aittomäki K; Bojesen SE; Shah M; Dunning AM; Rhenius V; Hall P; Czene K; Brand JS; Darabi H; Chang-Claude J; Rudolph A; Nordestgaard BG; Couch FJ; Hart SN; Figueroa J; García-Closas M; Fasching PA; Beckmann MW; Li J; Liu J; Andrulis IL; Winqvist R; Pylkäs K; Mannermaa A; Kataja V; Lindblom A; Margolin S; Lubinski J; Dubrowinskaja N; Bolla MK; Dennis J; Michailidou K; Wang Q; Easton DF; Pharoah PD; Schmidt MK; Nevanlinna H
    Breast Cancer Res; 2016 Oct; 18(1):98. PubMed ID: 27716369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition.
    Fredlund E; Staaf J; Rantala JK; Kallioniemi O; Borg A; Ringnér M
    Breast Cancer Res; 2012 Jul; 14(4):R113. PubMed ID: 22839103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ECM Remodeling in Breast Cancer with Different Grade: Contribution of 2D-DIGE Proteomics.
    Moriggi M; Giussani M; Torretta E; Capitanio D; Sandri M; Leone R; De Palma S; Vasso M; Vozzi G; Tagliabue E; Gelfi C
    Proteomics; 2018 Dec; 18(24):e1800278. PubMed ID: 30353998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of key tumor stroma-associated transcriptional signatures correlated with survival prognosis and tumor progression in breast cancer.
    Uddin MN; Wang X
    Breast Cancer; 2022 May; 29(3):541-561. PubMed ID: 35020130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcription factors zeb1, twist and snai1 in breast carcinoma.
    Soini Y; Tuhkanen H; Sironen R; Virtanen I; Kataja V; Auvinen P; Mannermaa A; Kosma VM
    BMC Cancer; 2011 Feb; 11():73. PubMed ID: 21324165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
    Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Loo LWM; Jia W; Obata Y; Yu H
    Breast Cancer Res Treat; 2018 Sep; 171(2):261-271. PubMed ID: 29845475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
    Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
    Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
    Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
    Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.
    Kimbung S; Johansson I; Danielsson A; Veerla S; Egyhazi Brage S; Frostvik Stolt M; Skoog L; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Loman N; Malmström PO; Söderberg M; Walz TM; Fernö M; Hatschek T; Hedenfalk I;
    Clin Cancer Res; 2016 Jan; 22(1):146-57. PubMed ID: 26276891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A genomic ruler to assess oncogenic transition between breast tumor and stroma.
    Dhage S; Ernlund A; Ruggles K; Axelrod D; Berman R; Roses D; Schneider RJ
    PLoS One; 2018; 13(10):e0205602. PubMed ID: 30325954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion.
    Vellinga TT; den Uil S; Rinkes IH; Marvin D; Ponsioen B; Alvarez-Varela A; Fatrai S; Scheele C; Zwijnenburg DA; Snippert H; Vermeulen L; Medema JP; Stockmann HB; Koster J; Fijneman RJ; de Rooij J; Kranenburg O
    Oncogene; 2016 Oct; 35(40):5263-5271. PubMed ID: 26996663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The fibromatosis signature defines a robust stromal response in breast carcinoma.
    Beck AH; Espinosa I; Gilks CB; van de Rijn M; West RB
    Lab Invest; 2008 Jun; 88(6):591-601. PubMed ID: 18414401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
    El-Gendi SM; Mostafa MF; El-Gendi AM
    Pathol Oncol Res; 2012 Apr; 18(2):459-69. PubMed ID: 22057638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
    Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
    Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers.
    Yao M; Yu E; Staggs V; Fan F; Cheng N
    Mod Pathol; 2016 Aug; 29(8):810-23. PubMed ID: 27125354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
    Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.